Instructional Biology"Bespoke" is a word borrowed from tailoring, and the borrowing is more useful than it might first seem. A bespoke suit isn't a standard size adjusted slightly to fit you better — it's built from your measurements from the first cut. Most of modern pharmacology works the other way around: a standard therapy, developed against a population average, occasionally adjusted afterward for body weight or an obvious contraindication. Closer to alterations than to a bespoke build.
We think the next era of therapeutics looks more like the tailoring analogy than the alterations one — not because customization is fashionable, but because the biology underneath actually varies enough, person to person, that a single fixed design was always going to leave real signal on the table.
What "bespoke" actually requires
Genuine bespoke therapeutics — not just genotyping someone into a slightly smaller population bucket — requires two things the field hasn't historically had together. The first is a way of representing biological signaling with enough resolution to capture individual variation: not just whether a person carries a particular genetic marker, but how their specific signaling network is actually behaving relative to a broader evidence base. The second is a design process — in our case, the carrier (exosome) manufacturing system — flexible enough to act on that resolution, rather than collapsing it back into a population-level decision the moment it's time to actually choose a therapy.
This is the gap our Signaling Cascade Knowledge Graph is built to address — a structured, evidence-weighted representation of biological relationships detailed enough to hold individual context, instead of flattening every case into the same set of population-level assumptions.
Why now, specifically
The idea of individualized medicine isn't new; the phrase has circulated for well over a decade. What's changed is the practical machinery underneath it. Continuous biosensing, richer genomic and proteomic data, and computational tools capable of reasoning over that data at scale have all matured substantially in the past few years — meaningfully more than in the prior 30. The intent behind "bespoke medicine" has existed for a long time. The infrastructure to actually deliver on it is only recently becoming real.
Patent Cliff 2.0, which we've written about separately, adds a second, less sentimental reason this shift is arriving now: the economics of finding one more single-target blockbuster to replace an expiring one are getting harder every cycle, while the cost of building reusable, individualized reasoning infrastructure doesn't face the same expiration problem a composition-of-matter patent does. Necessity and capability are converging on the same answer from two different directions.
What we're not claiming
None of this is a claim that bespoke therapeutics are available today, from us or from anyone else at real clinical scale. What exists right now is an increasingly credible research direction, a maturing set of enabling technologies, and — we think — a genuine opportunity for a company willing to build the reasoning infrastructure this shift actually requires, patiently and validated one evidence gate at a time, rather than promising the destination before the road is built.